Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
Public ClinicalTrials.gov record NCT00470834. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Double-Blind Parallel Group Study Comparing Casodex (or Generic Equivalent) 50mg Plus Placebo to Casodex (or Generic Equivalent) 50mg Plus Dutasteride 3.5mg Administered for 18 Months to Men With Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Dutasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT) the male hormone that leads to benign prostate growth. By blocking the conversion of testosterone to DHT, dutasteride could allow bicalutamide to be a more effective anti-androgen thus prolonging bicalutamide's efficacy.
Study identification
- NCT ID
- NCT00470834
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 127 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 90 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2007 (Type not available)
- Primary completion
- Feb 2013 (Actual)
- Completion
- Feb 2013 (Actual)
- Last update posted
- Feb 27, 2017
2007 – 2013
United States locations
- U.S. sites
- 47
- U.S. states
- 26
- U.S. cities
- 46
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Homewood | Alabama | 35209 | — |
| GSK Investigational Site | Huntsville | Alabama | 35801 | — |
| GSK Investigational Site | Little Rock | Arkansas | 72205 | — |
| GSK Investigational Site | Anaheim | California | 92801 | — |
| GSK Investigational Site | Fresno | California | 93720 | — |
| GSK Investigational Site | San Bernardino | California | 92404 | — |
| GSK Investigational Site | San Diego | California | 92101 | — |
| GSK Investigational Site | Denver | Colorado | 80211 | — |
| GSK Investigational Site | Washington D.C. | District of Columbia | 20307 | — |
| GSK Investigational Site | Aventura | Florida | 33180 | — |
| GSK Investigational Site | Daytona Beach | Florida | 32114 | — |
| GSK Investigational Site | Orlando | Florida | 32803 | — |
| GSK Investigational Site | Galesburg | Illinois | 61401 | — |
| GSK Investigational Site | Evansville | Indiana | 47713 | — |
| GSK Investigational Site | Fort Wayne | Indiana | 46825 | — |
| GSK Investigational Site | Jeffersonville | Indiana | 47130 | — |
| GSK Investigational Site | Overland Park | Kansas | 66211 | — |
| GSK Investigational Site | New Orleans | Louisiana | 70112 | — |
| GSK Investigational Site | Shreveport | Louisiana | 71106 | — |
| GSK Investigational Site | Annapolis | Maryland | 21401 | — |
| GSK Investigational Site | Watertown | Massachusetts | 02472 | — |
| GSK Investigational Site | Chaska | Minnesota | 55318 | — |
| GSK Investigational Site | Minneapolis | Minnesota | 55455 | — |
| GSK Investigational Site | St Louis | Missouri | 63136 | — |
| GSK Investigational Site | Omaha | Nebraska | 68114 | — |
| GSK Investigational Site | Las Vegas | Nevada | 89148 | — |
| GSK Investigational Site | Albany | New York | 12208 | — |
| GSK Investigational Site | Garden City | New York | 11530 | — |
| GSK Investigational Site | Manhasset | New York | 11030 | — |
| GSK Investigational Site | New York | New York | 10016 | — |
| GSK Investigational Site | Syracuse | New York | 13210 | — |
| GSK Investigational Site | Concord | North Carolina | 28025 | — |
| GSK Investigational Site | Columbus | Ohio | 43214 | — |
| GSK Investigational Site | Bala-Cynwyd | Pennsylvania | 19004 | — |
| GSK Investigational Site | Lancaster | Pennsylvania | 17604 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19107 | — |
| GSK Investigational Site | Myrtle Beach | South Carolina | 29572 | — |
| GSK Investigational Site | Memphis | Tennessee | 38119 | — |
| GSK Investigational Site | Houston | Texas | 77074 | — |
| GSK Investigational Site | San Antonio | Texas | 78229 | — |
| GSK Investigational Site | Norfork | Virginia | 23502 | — |
| GSK Investigational Site | Richmond | Virginia | 23235 | — |
| GSK Investigational Site | Virginia Beach | Virginia | 23454 | — |
| GSK Investigational Site | Williamsburg | Virginia | 23185 | — |
| GSK Investigational Site | Seattle | Washington | 98166 | — |
| GSK Investigational Site | Seattle | Washington | 98195-6015 | — |
| GSK Investigational Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00470834, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 27, 2017 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00470834 live on ClinicalTrials.gov.